The Business Research Company’s report on the Visceral Leishmaniasis Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the visceral leishmaniasis industry?
The rise in malnutrition is expected to propel the growth of the visceral leishmaniasis market going forward. Malnutrition is a health condition caused by inadequate or unbalanced nutrient intake essential for proper body functioning. The rise in malnutrition is due to food insecurity, as it limits access to nutritious food, leading to undernourishment and micronutrient deficiencies, which weaken the immune system. Malnutrition impairs immune function, making the body more vulnerable to infections such as visceral leishmaniasis. Nutrient deficiencies weaken defense mechanisms, increasing the risk of severe disease and complications. For instance, in July 2024, according to the Food and Agriculture Organization, an Italy-based specialized agency of the United Nations, the number of undernourished people rose to 723.8 million in 2022, up from 708.7 million in 2021. Therefore, the rise in malnutrition is driving the growth of the visceral leishmaniasis market.
Access Your Free Sample of the Global Visceral Leishmaniasis Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp
What is the estimated market size of the visceral leishmaniasis sector by 2029, based on current forecasts?
The visceral leishmaniasis market size has grown strongly in recent years. It will grow from $1.00 billion in 2024 to $1.06 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to increasing disease burden, rising government funding, the introduction of amphotericin B, development of miltefosine, growing awareness campaigns, improved healthcare access in endemic regions, and establishment of public-private partnerships.
The visceral leishmaniasis market size is expected to see strong growth in the next few years. It will grow to $1.33 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing investment in vaccine development, enhanced global disease surveillance programs, increasing public-private collaborations, improved funding for neglected tropical diseases and development of gene-based therapies. Major trends in the forecast period include clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing, artificial intelligence (AI)-driven drug discovery, nanotechnology-enhanced drug delivery, next-generation sequencing for parasite analysis, wearable biosensors for early detection, blockchain for medical supply chain management, smartphone-based diagnostic tools and three-dimensional (3D) bioprinting for personalized treatment research.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=23573&type=smp
Who are the top players in the visceral leishmaniasis market?
Major companies operating in the visceral leishmaniasis market are Pfizer Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd, Xellia Pharmaceuticals, Knight Therapeutics Inc, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, TLC.
What are the major trends in the visceral leishmaniasis market?
Major companies operating in the visceral leishmaniasis market are focusing on developing advancements in treatment options, such as antiparasitic drugs to improve efficacy and enhance patient accessibility, particularly in endemic regions. Antiparasitic drugs are medications used to treat infections caused by parasites, by targeting the parasite’s biological functions and disrupting its growth, reproduction, or survival within the host. For instance, in February 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, received World Health Organization (WHO) prequalification approval for the active pharmaceutical ingredient (API) and formulation of miltefosine for the treatment of leishmaniasis or kala-azar. Miltefosine is an oral antiparasitic drug that works by disrupting the parasite’s cell membrane and interfering with its metabolism, leading to cell death. It also inhibits parasite growth and survival, making it an effective oral treatment option for visceral leishmaniasis or kala azar.
Which geography holds the highest visceral leishmaniasis market share?
North America was the largest region in the visceral leishmaniasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report
How do different segments contribute to the overall expansion of the visceral leishmaniasis market?
The visceral leishmaniasis market covered in this report is segmented –
1) By Treatment: Antiparasitic, Antifungal, Other Treatments
2) By Diagnosis Method: Serological Tests, Molecular Tests, Microscopy, Culture Methods
3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Antiparasitic: Pentavalent Antimonials, Miltefosine, Paromomycin, Sitamaquine, Combination Therapy
2) By Antifungal: Amphotericin B, Liposomal Amphotericin B (AmBisome), Azoles, Echinocandins, Polyenes
3) By Other Treatments: Immunotherapy, Monoclonal Antibodies, Vaccine-Based Approaches, Photodynamic Therapy, Gene Therapy
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23573
What defines the structure and scope of the visceral leishmaniasis market?
Visceral leishmaniasis, also known as kala-azar, is a severe parasitic disease caused by Leishmania species, transmitted through infected sandfly bites. It affects internal organs such as the spleen, liver and bone marrow, causing prolonged fever, weight loss, anemia and organ enlargement. If untreated, it can be fatal, making early diagnosis and treatment crucial.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
